Cyxone raises SEK 1 million in a second directed share issue under the agreement with Dr Kask to jointly develop a new treatment of Covid-19
Cyxone AB (publ), a Swedish biotech company engaged in developing new treatments for autoimmune diseases, has today resolved on a directed share issue of 214,858 shares, with a net proceed of SEK 1 million. The share issue is made under the investment option agreement with Dr Kalev Kask, which has been put in place to jointly develop a new treatment for Covid-19.The board of directors of Cyxone has resolved on a directed share issue in accordance with the investment option agreement that the Company entered into with Dr Kalev Kask, which was described in more detail in the Company’s press